# Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

> **NCT03642496** · EARLY_PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 18 (estimated)

## Conditions studied

- B-Cell Malignancies

## Interventions

- **BIOLOGICAL:** Low dose ET019002- T Cells
- **BIOLOGICAL:** Middle dose ET019002- T Cells
- **BIOLOGICAL:** High dose ET019002- T Cells

## Key facts

- **NCT ID:** NCT03642496
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-19
- **Primary completion:** 2020-08-19
- **Final completion:** 2020-09-20
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2018-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03642496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03642496, "Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03642496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*